US 11,851,418 B2
Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
Matthias Eckhardt, Biberach an der Riss (DE); Maude Giroud, Basel (CH); Camilla Mayer, Warthausen (DE); Holger Wagner, Mettenberg (DE); and Dieter Wiedenmayer, Bieberach an der Riss (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Feb. 11, 2021, as Appl. No. 17/173,212.
Claims priority of application No. 20157257 (EP), filed on Feb. 13, 2020.
Prior Publication US 2021/0276976 A1, Sep. 9, 2021
Int. Cl. C07D 401/14 (2006.01); C07D 403/14 (2006.01); A61K 45/06 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 45/06 (2013.01); C07D 403/14 (2013.01)] 10 Claims
 
1. A compound of formula (I),

OG Complex Work Unit Chemistry
wherein
R is selected from the group consisting of

OG Complex Work Unit Chemistry
R1 is selected from the group consisting of H and F;
the moiety =A1-CR=A2- is selected from the group consisting of ═N—CR═N—, ═N—CR═CH— and ═CH—CR═N—; and
the moiety -L1=L2- is selected from the group consisting of —N═N—, —N═CH— and —CH═N—;
and/or its tautomers
or a pharmaceutically acceptable salt thereof.